Enhanced Protective Efficacy of a Chimeric Form of the Schistosomiasis Vaccine Antigen Sm-TSP-2
Figure 4
Worm burdens of vaccinated C57BL/6 mice.
All vaccinees were necropsied on day 91, 7 weeks post-challenge. Worms were perfused from the vasculature with PBS into petri dishes and counted. Reductions and significance (*P<0.05; **P<0.01; *** P<0.001) are represented relative to the Maltose Binding Protein (MBP) control group. (A) Trial 1 total worms. (B) Trial 2 total worms.